This section contains news items that were not issued as a press release.
- Thursday, 3 May 2012
- NIH launches collaborative program with industry and researchers Scientists will gain access to select compounds from Pfizer, AstraZeneca, and Lilly
- Tuesday, 1 May 2012
- Axerion Therapeutics and AstraZeneca to Develop and Commercialize a Biologic Approach for the Treatment of Alzheimer’s Disease Axerion Therapeutics, Inc., a private Connecticut-based biotechnology company, and MedImmune the global biologics arm of AstraZeneca, announced today that they have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.
- Monday, 23 April 2012
- AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout AstraZeneca and Ardea Biosciences, Inc. (Ardea) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics. Ardea’s clinically most advanced product candidate, lesinurad (formerly known as RDEA594), is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.
- Monday, 16 April 2012
- Conformetrix and AstraZeneca sign collaborative agreement Conformetrix Ltd, a leader in optimising drug discovery and design, and AstraZeneca announced today that they have signed a research collaboration agreement under which Conformetrix’s proprietary NMR-based technology will be applied across AstraZeneca’s pre-clinical therapeutic pipeline to enhance lead discovery and hit identification.
- Thursday, 12 April 2012
- AstraZeneca and Liverpool School of Tropical Medicine combine resources in the fight against Neglected Tropical Diseases AstraZeneca and the Liverpool School of Tropical Medicine announce a research agreement aimed at finding new medicines to treat river blindness and lymphatic filariasis, which are neglected tropical diseases (NTDs) that affect millions of people.
- Thursday, 12 April 2012
- AstraZeneca and DNDi to Collaborate on Drug Screening for Neglected Tropical Diseases AstraZeneca and the Drugs for Neglected Diseases initiative (DNDi) announce an agreement to collaborate on drug-compound screening for leishmaniasis, Chagas disease, and sleeping sickness, three neglected tropical diseases (NTDs) which together affect nearly 10 million people worldwide.
- Thursday, 5 April 2012
- Collaboration’s exciting discovery could be novel drug target A first-class collaboration between AstraZeneca and academia, Karolinska Institute, has resulted in a breakthrough discovery published in the Journal of Biological Chemistry.
- Monday, 2 April 2012
- AstraZeneca and Amgen announce collaboration to jointly develop and commercialise clinical-stage inflammation portfolio AstraZeneca and Amgen today announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).
- Monday, 12 March 2012
- AstraZeneca and Nobel Media bring Nobel Laureate Peter Doherty to India The AstraZeneca Nobel Medicine Initiative visits India for the first time.
- Tuesday, 7 February 2012
- AstraZeneca Appoints Dr. Mike Poole to Lead New ‘Virtual’ Neuroscience Innovative Medicines Unit AstraZeneca today announced the appointment of Dr. Mike Poole to lead its newly created virtual Neuroscience Innovative Medicines Unit (iMed) with the responsibility for a portfolio of large and small molecule projects.